Open Access<p>Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma</p>
Author(s) -
Hui Shi,
Shuo Sun,
Haoyue Xu,
Zongren Zhao,
Zhengzhong Han,
Jinping Jia,
Dongmei Wu,
Jun Lu,
Hongmei Liu,
Rutong Yu
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s243878
Subject(s) - temozolomide , glioma , small interfering rna , in vivo , cancer research , apoptosis , pharmacology , cytotoxicity , chemistry , medicine , cell culture , biology , in vitro , transfection , biochemistry , microbiology and biotechnology , genetics
Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Therefore, to limit TMZ resistance in glioma, an angiopep-2 (A2)-modified polymeric micelle (A2PEC) embedded with TMZ and a small interfering RNA (siRNA) targeting PLK1 (siPLK1) was developed (TMZ-A2PEC/siPLK).